-
Mashup Score: 1
The FDA Oncologic Drugs Advisory Committee on Thursday voted against questions regarding the benefits vs. risks of two cancer treatments for which new drug applications have been filed.The panel concluded 9-4 that the current benefits of the oral, irreversible tyrosine kinase inhibitor poziotinib do not outweigh its risks for treatment of patients with non-small cell lung cancer with HER2 exon 20
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA clears IND application for cancer therapeutic IMT-009 - 2 year(s) ago
FDA cleared an investigational new drug application for IMT-009, a fully human monoclonal antibody that combats inhibitory T-cell target CD161, according to a company press release.The IND clearance applies to patients who are refractory to standard-of-care therapy, or ineligible for or refused another existing treatment option.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA CLEARANCE: IND application for #cancer therapeutic IMT-009. https://t.co/kG1iwZNsMU #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #cancertherapeutic @ImmunitasTx #IND #FDACleared
-
-
Mashup Score: 0Gene therapy fails to significantly extend survival in ovarian cancer, topline data show - 2 year(s) ago
A phase 3 trial of ofranergene obadenovec in platinum-resistant ovarian cancer failed to meet its primary endpoints of statistically significant improvement in PFS and OS, according to topline data released by the agent’s manufacturer.Ofranergene obadenovec, or ofra-vec (VB-111, VBL Therapeutics), is an investigational, targeted anticancer gene-therapy designed to treat multiple types of
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#OvarianCancerAwarenessMonth FAILED: A phase 3 trial of #OfranergeneObadenovec (VB-111, @VBLTherapeutic) in platinum-resistant ovarian cancer. https://t.co/BoZCtpKGoB #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #ovariancancer #genetherapy #cancer
-
-
Mashup Score: 0FDA approves Retevmo for lung cancer subset - 2 year(s) ago
The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.The indication applies to use of selpercatinib (Retevmo, Eli Lilly) by adults with locally advanced or metastatic RET fusion-positive NSCLC as detected by an FDA-approved test.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA APPROVED: Retevmo for lung cancer subset. https://t.co/s1U6ABuXK5 #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #selpercatinib #Retevmo @Eli Lilly #lungcancer #nonsmallcelllungcancer #metastaticlungcancer
-
-
Mashup Score: 3
National Comprehensive Cancer Network has updated its recommendations on COVID-19 vaccination for patients with cancer.The revised guidance, available online at nccn.org/covid-19, includes information on bivalent vaccines and protection for children with cancer, according to an NCCN press release.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@NCCN Update: NEW recommendations on COVID-19 vaccination for cancer patients. https://t.co/0nhaxsakn5 #Covid19 #Vaccination #CancerPatients #Cancer #MedTwitter #MedEd #MedEducation #Oncology #OncAlert
-
-
Mashup Score: 0
Long-course androgen depravation therapy extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, results of the randomized phase 3 RADICALS-HD trial showed.The findings, presented at ESMO Congress, also revealed no significant improvement in metastasis-free survival (MFS) among men with prostate cancer who received short-course ADT
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Long-course ADT plus radiotherapy provides survival benefits after #prostatectomy. https://t.co/YYDdYT68GO #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #ESMO22 @myESMO
-
-
Mashup Score: 1
MILAN — At the ESCRS meeting, Sheraz Daya, MD, spoke about Isopure (PhysIOL/BVI), an IOL that is classified as monofocal plus but exceeds the standards for extended depth of focus lenses.
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
WATCH: IOL terminology should be addressed by #OphthalmicCommunity. https://t.co/7cmvMpuxnm #ESCRS @ESCRSofficial #ESCRS2022 #ophthalmology #eyecare #ophthalmologyprofessionals #eyecareprofessionals #MedTwitter #EyeHealth #MedEducation #MedEd
-
-
Mashup Score: 0AACR report: Cancer deaths decline 2.3% amid treatment advances, but disparities persist - 2 year(s) ago
In its 12th annual Cancer Progress Report, American Association for Cancer Research outlined substantial strides against cancer, including a 2.3% decrease in cancer deaths between 2016 and 2019.Major advances and innovations in cancer treatment have also led to an unprecedented number of Americans living longer and fuller lives after diagnosis, according to the report.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
12th Annual #CancerProgressReport: 2.3% decrease in cancer deaths between 2016 and 2019, but disparities persist. https://t.co/qzuffCDyK6 @AACR @AACRFoundation #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #ResearchSavesLives
-
-
Mashup Score: 0FDA approves Pedmark to prevent cisplatin-related ototoxicity among children with cancer - 2 year(s) ago
The FDA approved sodium thiosulfate to reduce risk for cisplatin-associated ototoxicity among certain children with cancer.The indication allows use of the agent by patients aged 1 month or older with localized, nonmetastatic solid tumors.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA APPROVED: #SodiumThiosulfate (#Pedmark, #FennecPharmaceuticals) to reduce risk for cisplatin-associated ototoxicity among certain children with #cancer. https://t.co/7LR7Cb4sjd @US_FDA #childhoodcancer #Cisplatin #Hepatoblastoma #MedTwitter #MedEd #MedEducation #OncAlert
-
-
Mashup Score: 2
Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.The findings — presented at European Society for Medical Oncology Congress — showed benefit with the combination despite the fact a high percentage of patients in the control arm received
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#OvarianCancerAwarenessMonth Combing maintenance therapy, #olaparib (Lynparza; @AstraZeneca, @Merck), and #bevacizumab (@Avastin, @Genentech) extended survival for women with advanced #ovariancancer. https://t.co/8oY9F1YMRz #MedTwitter #MedEd #MedEducation #Oncology #OncAlert
-
.@US_FDA advisory panel votes AGAINST drugs for #lungcancer, #multiplemyeloma subgroups. https://t.co/ik3eHjnui9 #MedTwitter #MedEd #MedEducation #Oncology #OncAlert @DukeMedSchool